Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2173893 | 0.76 | GRM5 (0.56) | GRM5GABRA2GABRB2 | |
| SCHEMBL2177266 | 0.75 | GRM5 (0.58) | GRM5GABRA2GABRB2KCNH2 | |
| SCHEMBL4631058 | 0.75 | GRM5 (0.71) | GRM5GABRA2GABRB2KCNH2 | |
| Hydrochloric Acid SCHEMBL4629671 | 0.74 | GRM5 (0.69) | GRM5GABRA2GABRB2KCNH2 | |
| SCHEMBL11685483 | 0.71 | GABRA2 (0.49) | GRM5GABRA2GABRB2NOTUMALDH1A1 | |
| SCHEMBL10900906 | 0.66 | ALDH1A1 (0.51) | GRM5KCNH2NOTUMALDH1A1 | |
| SCHEMBL981050 | 0.66 | PDE3B (0.38) | GRM5 | |
| SCHEMBL4630888 | 0.65 | GRM5 (0.73) | GRM5KCNH2 | |
| SCHEMBL3758942 | 0.63 | — | — | |
| SCHEMBL28277768 | 0.62 | GRM5 (0.41) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606277-B8 | IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-10-15 | — | — | EP | disclosed |
| EP-1606277-B1 | IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-05-14 | — | — | EP | disclosed |
| US-7153874-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1606277-A1 | IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-21 | — | — | EP | disclosed |
| US-20040229917-A1 | Imidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-18 | — | — | US | disclosed |
| WO-2004080998-A1 | IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229917-A1 | Imidazole derivatives | GRIK4, GRIA4, GRIK5 | GRM5 10/4885GABRA2 137/4885GABRB2 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.